Literature DB >> 20958061

The constitutive activation of Jak2-V617F is mediated by a π stacking mechanism involving phenylalanines 595 and 617.

Kavitha Gnanasambandan1, Andrew Magis, Peter P Sayeski.   

Abstract

Somatic mutations in the Jak2 allele that lead to constitutive kinase activation of the protein have been identified in human disease conditions such as the myeloproliferative neoplasms (MPNs). The most common mutation in these patients is a V617F substitution mutation, which is believed to play a causative role in the MPN pathogenesis. As such, identifying the molecular basis for the constitutive activation of Jak2-V617F is important for understanding its clinical implications and potential treatment. Here, we hypothesized that conversion of residue 617 from Val to Phe resulted in the formation of novel π stacking interactions with neighboring Phe residues. To test this, we first examined the Jak2 structure via molecular modeling and identified a potential π stacking interaction between F594, F595, and F617. Disruption of this interaction through site-directed mutagenesis impaired Jak2 autophosphorylation, Jak2-dependent gene transcription, and in vitro kinase activity of the Jak2-V617F protein. Further, substitution of F594 and F595 with Trp did not affect Jak2 function significantly, but replacement with charged residues did, showing the importance of aromaticity and hydropathy index conservation at these positions. Using molecular dynamics (MD) simulations, we found that the π stacking interaction between residues 595 and 617 in the Jak2-V617F protein was of much greater energy and conformed to the properties of π stacking, relative to the Jak2-WT or Jak2-V617F/F594A/F595A. In summary, we have identified a π stacking interaction between F595 and F617 that is specific to and is critical for the constitutive activation of Jak2-V617F.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20958061      PMCID: PMC2982877          DOI: 10.1021/bi1014858

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  42 in total

1.  Scalable molecular dynamics with NAMD.

Authors:  James C Phillips; Rosemary Braun; Wei Wang; James Gumbart; Emad Tajkhorshid; Elizabeth Villa; Christophe Chipot; Robert D Skeel; Laxmikant Kalé; Klaus Schulten
Journal:  J Comput Chem       Date:  2005-12       Impact factor: 3.376

2.  pi-Stacking interactions. Alive and well in proteins.

Authors:  G B McGaughey; M Gagné; A K Rappé
Journal:  J Biol Chem       Date:  1998-06-19       Impact factor: 5.157

3.  Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis.

Authors:  H Neubauer; A Cumano; M Müller; H Wu; U Huffstadt; K Pfeffer
Journal:  Cell       Date:  1998-05-01       Impact factor: 41.582

4.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

Authors:  Chloé James; Valérie Ugo; Jean-Pierre Le Couédic; Judith Staerk; François Delhommeau; Catherine Lacout; Loïc Garçon; Hana Raslova; Roland Berger; Annelise Bennaceur-Griscelli; Jean Luc Villeval; Stefan N Constantinescu; Nicole Casadevall; William Vainchenker
Journal:  Nature       Date:  2005-04-28       Impact factor: 49.962

5.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

6.  Identification of an acquired JAK2 mutation in polycythemia vera.

Authors:  Runxiang Zhao; Shu Xing; Zhe Li; Xueqi Fu; Qingshan Li; Sanford B Krantz; Zhizhuang Joe Zhao
Journal:  J Biol Chem       Date:  2005-04-29       Impact factor: 5.157

7.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

Authors:  E Joanna Baxter; Linda M Scott; Peter J Campbell; Clare East; Nasios Fourouclas; Soheila Swanton; George S Vassiliou; Anthony J Bench; Elaine M Boyd; Natasha Curtin; Mike A Scott; Wendy N Erber; Anthony R Green
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

8.  Dependence on the motif YIPP for the physical association of Jak2 kinase with the intracellular carboxyl tail of the angiotensin II AT1 receptor.

Authors:  M S Ali; P P Sayeski; L B Dirksen; D J Hayzer; M B Marrero; K E Bernstein
Journal:  J Biol Chem       Date:  1997-09-12       Impact factor: 5.157

9.  A gain-of-function mutation of JAK2 in myeloproliferative disorders.

Authors:  Robert Kralovics; Francesco Passamonti; Andreas S Buser; Soon-Siong Teo; Ralph Tiedt; Jakob R Passweg; Andre Tichelli; Mario Cazzola; Radek C Skoda
Journal:  N Engl J Med       Date:  2005-04-28       Impact factor: 91.245

10.  Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop.

Authors:  J Feng; B A Witthuhn; T Matsuda; F Kohlhuber; I M Kerr; J N Ihle
Journal:  Mol Cell Biol       Date:  1997-05       Impact factor: 4.272

View more
  18 in total

1.  ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation.

Authors:  Henrik M Hammarén; Daniela Ungureanu; Jean Grisouard; Radek C Skoda; Stevan R Hubbard; Olli Silvennoinen
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-30       Impact factor: 11.205

Review 2.  Molecular insights into regulation of JAK2 in myeloproliferative neoplasms.

Authors:  Olli Silvennoinen; Stevan R Hubbard
Journal:  Blood       Date:  2015-03-30       Impact factor: 22.113

3.  Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations.

Authors:  Henrik M Hammarén; Anniina T Virtanen; Bobin George Abraham; Heidi Peussa; Stevan R Hubbard; Olli Silvennoinen
Journal:  J Allergy Clin Immunol       Date:  2018-08-06       Impact factor: 10.793

4.  Mechanism of homodimeric cytokine receptor activation and dysregulation by oncogenic mutations.

Authors:  Stephan Wilmes; Maximillian Hafer; Joni Vuorio; Julie A Tucker; Hauke Winkelmann; Sara Löchte; Tess A Stanly; Katiuska D Pulgar Prieto; Chetan Poojari; Vivek Sharma; Christian P Richter; Rainer Kurre; Stevan R Hubbard; K Christopher Garcia; Ignacio Moraga; Ilpo Vattulainen; Ian S Hitchcock; Jacob Piehler
Journal:  Science       Date:  2020-02-07       Impact factor: 47.728

Review 5.  A structure-function perspective of Jak2 mutations and implications for alternate drug design strategies: the road not taken.

Authors:  K Gnanasambandan; P P Sayeski
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

6.  Identification of novel SAR properties of the Jak2 small molecule inhibitor G6: significance of the para-hydroxyl orientation.

Authors:  Rebekah Baskin; Meghanath Gali; Sung O Park; Zhizhuang Joe Zhao; György M Keseru; Kirpal S Bisht; Peter P Sayeski
Journal:  Bioorg Med Chem Lett       Date:  2011-12-21       Impact factor: 2.823

7.  Molecular basis for pseudokinase-dependent autoinhibition of JAK2 tyrosine kinase.

Authors:  Yibing Shan; Kavitha Gnanasambandan; Daniela Ungureanu; Eric T Kim; Henrik Hammarén; Kazuo Yamashita; Olli Silvennoinen; David E Shaw; Stevan R Hubbard
Journal:  Nat Struct Mol Biol       Date:  2014-06-11       Impact factor: 15.369

8.  Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F.

Authors:  Rajintha M Bandaranayake; Daniela Ungureanu; Yibing Shan; David E Shaw; Olli Silvennoinen; Stevan R Hubbard
Journal:  Nat Struct Mol Biol       Date:  2012-07-22       Impact factor: 15.369

9.  A shift in the salt bridge interaction of residues D620 and E621 mediates the constitutive activation of Jak2-H538Q/K539L.

Authors:  Kavitha Gnanasambandan; Andrew T Magis; Peter P Sayeski
Journal:  Mol Cell Biochem       Date:  2012-05-15       Impact factor: 3.842

10.  Ab initio modeling and experimental assessment of Janus Kinase 2 (JAK2) kinase-pseudokinase complex structure.

Authors:  Xiaobo Wan; Yue Ma; Christopher L McClendon; Lily Jun-shen Huang; Niu Huang
Journal:  PLoS Comput Biol       Date:  2013-04-04       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.